Top-Rated Free Essay

Biopure Case Study

Satisfactory Essays
Biopure Corporation have two new products that are Oxyglobin and Hemopure. Oxyglobin is the first blood substitute for the veterinary market and is ready for launch. Hemopure is another new blood substitute for the human market and will take two years to launch. Ted Jacobs, VP (Human Clinical Trials), is concerned about creating an unrealistic price expectation for Hemopure by marketing Oxyglobin before Hemopure. Whereas, Andy Wright, VP (Veterinary Products), believes that selling Oxyglobin has benefits as it will generate revenues that can be used for smooth operations of company & for launching Hemopure and learning how to market Hemopure. Carl Rausch, (President and CEO) of Biopure, has to decide whether the launch of Oxyglobin would be beneficial for the company without jeopardizing the future of Hemopure.
Recommendation:
I think that launching Oxyglobin has many benefits for the company. Even though the veterinary market is small and price sensitive, being the first mover will make a huge difference and impact the company’s reputation in a positive way. 84% of veterinary doctors complained about the lack of alternatives to the blood transfusion in the market & there will be no competition for at least five years. Waiting for Hemopure can put the company in a risk because of the possibility of competitors’ entrance to the veterinary market. Once Oxyglobin achieves its purpose and satisfies the veterinary doctors and pet owners, the success of Oxyglobin will help Biopure to easily launch Hemopure and attract the human market.
Basis of Recommendation:
SWOT ANALYSIS OF HEMOPURE & OXYGLOBIN
STRENGTHS
WEEKNESSES
HEMOPURE
OXYGLOBIN
HEMOPURE
OXYGLOBIN
Eliminating need of Blood typing
Eliminating need of Blood Typing
Short Life in body (2 - 7 days)
Short Life in body (2 - 7 days)
Free from Contamination
Free from Contamination
Max dosage of 5 - 10 Units
Max dosage of 5 - 10 Units
Shelf Life of 2 Years
Shelf Life of 2 Years
No Distribution Network
No distribution Network
RBC 100% efficient from Start
RBC 100% efficient from Start
No prior exp. In product launch
No prior exp. In product launch
Stored at Room Temperature
Stored at Room Temperature

Small RBC - Better Reach
Small RBC - Better Reach

Made from Bovine Blood (Availability & Margin)
Made from Bovine Blood (Availability & Margin)

OPPERTUNITIES
THREATS
HEMOPURE
OXYGLOBIN
HEMOPURE
OXYGLOBIN
Large & Realistic Market
No Competition
Competition (2 More Companies)
Small & price sensitive mkt. Can be launched immediately
FDA By Laws
Vet Reluctance for Use
Price: $600 - $800
Price: $200
2 Years in Launch Market Potential:-
Market Potential:
Made from Bovine Blood (Negative Perception)
Made from Bovine Blood (Negative Perception)

Marketing Strategy: Even though the surveys show that veterinarians recommend less-expensive treatments, 90% of pet owners are willing to know about all the available alternatives to treat their pets. Therefore, taking into account the advantages of Oxyglobin relative to alternatives, Oxyglobin should be priced at $200 per unit (matching price with Hemopure). Instead of selling through distributors, Biopure should directly sell through its sales forces (cost of distributing $10 -$15); by doing so, the company will save 30% on distributor’s margin ($60 per unit). Oxyglobin can be advertised through Vet Journals and Trade Shows. Hemopure can take advantage of brand image built by Oxyglobin. Revenue generated by Oxyglobin can be used for expanding Biopure’s production capacity. By the time Biopure is ready to launch Hemopure they can establish a robust marketing team & distribution channel and they will have on hand experience of launching new product.
HEMOPURE

No of Units (Transfusion)

Anonymous Donation (A)
5800000
Trauma taken as 100% (as we can store Hemopure in Ambulance (at room temp & shelf life 2 yrs.). Borderline Surgeries are included because Hemopure eliminates contamination risks.

Emergency Surgery (B)
1000000

Trauma ( C )
2000000

Borderline Transfusion Surgeries (D)
1500000

Market Potential (In Units) (E=A+B+C+D)
10300000

Price (Per Unit) (F)
600

Market Potential (in $ Value) (E*F)
6180000000

All the available units of RBC's were consumed in 1995. I am assuming that consumption remains same in 1999. So I am calculating Market Potential keeping the present level of consumption.

OXYGLOBIN Non Critical
Critical
Total
No of Vets (A)
14250
750
15000
Av. No of Transfusion (Per vet Care) (B)
17
150 Total No of Transfusion (C=A*B)
242250
112500
354750
Market Potential (Units) {D=(C/2.5%)*30%}
2907000
1350000
4257000
Price (Per Unit) ( E )
200
200 Potential Market (in $ Value) (D*E)
581400000
270000000
851400000

Price 1
Price 2
Price 3
Suggested Price (A)
100
150
200
Production Capacity (B)
300000
300000
300000
Fixed Cost ( C )
15000000
15000000
15000000
Bovine Blood Cost/Unit (D)
1.5
1.5
1.5
Approx. Distribution Cost ( E )
12.5
12.5
12.5
Total Variable Cost (F=D+E)
14
14
14
Contribution (G=A-F)
86
136
186
Break Even Point (H=C/G)
174419
110294
80645

You May Also Find These Documents Helpful

  • Powerful Essays

    Biopure Case Study

    • 2806 Words
    • 12 Pages

    Estimated Market Demand for Oxyglobin 13 Exhibit 3: Estimation of veterinary Market and per year 14 Exhibit 4: Financial Projections – Sensitivity Analysis 15 Executive Summary In 1998, Biopure Corporation is one of the three legitimate contenders in the emerging field of “blood substitutes”. Biopure has invested $200M on the R&D on blood substitutes in the past with its primary goal being the development of a human blood substitute ( Hemopure) but Its entry into animal market (Oxyglobin) had…

    • 2806 Words
    • 12 Pages
    Powerful Essays
  • Powerful Essays

    Biopure Case Study

    • 902 Words
    • 4 Pages

    Biopure Market Potential Exercise Suggested Solution Question 1) How would you revise the market potential for Hemopure? The best four-segment solution to the usage problem includes these categories: elective surgery; emergency surgery; in field trauma; and chronic anemia. Current Usage Change Potential Usage Trauma (in field) 200,000 *10 2,000,000 Currently only 10% of trauma cases get blood transfusions in the field. With better storage potential and no need for blood…

    • 902 Words
    • 4 Pages
    Powerful Essays
  • Powerful Essays

    Biopure Case Study

    • 2639 Words
    • 11 Pages

    Biopure Corporation Case Study Richard Addington PHD Table of Contents 1. Executive Summary 2. Situation Analysis a. Human Blood Demand b. Human Blood Pricing c. RBC limitations 3. Internal Environment d. Strengths and weaknesses of Oxyglobin e. Strengths and weaknesses of Hemopure 4. External/Competitive Environment f. Baxter g. Northfield h. Biopure 5. Animal Blood Market 6. Marketing Plan i. Positioning j. Pricing…

    • 2639 Words
    • 11 Pages
    Powerful Essays
  • Good Essays

    Biopure Case Study

    • 935 Words
    • 4 Pages

    In addressing the issue, the following were considered: a sensitivity analysis for potential consumption of different price series, associated revenues and costs, and gross profit from different distribution methods. It is recommended that Biopure: 1. Introduce Oxyglobin immediately at a price of $100 to veterinarians. 2. Have an independent sales force distribute the product to maximize profits. 3. Advertise Oxyglobin in both veterinarian journals and trade shows. 4. Establish…

    • 935 Words
    • 4 Pages
    Good Essays
  • Good Essays

    Biopure Case

    • 7016 Words
    • 29 Pages

    possible scenarios of Biopure’s products launching and provides marketing plan of the recommended one. The study shows that Biopure should immediately launch Oxyglobin rather than wait for Hemopure's FDA Approval then launch both products simultaneously. The proposed price for Oxyglobin is $300 per unit with promotion campaign from time to time. With this set price of immediate launch, Biopure will reach breakeven point for Oxyglobin in year 2000 with the amount of 2.13 million USD. Targeting market…

    • 7016 Words
    • 29 Pages
    Good Essays
  • Good Essays

    Biopure Case Study

    • 661 Words
    • 3 Pages

    units (1 million surgeries with requirements of 1-2 units / surgery). Trauma: Out of the 0.5 million trauma cases / year, currently only 10% received the blood on-time, while the remaining 90% had to wait until the victim arrived to the ER. We consider that this 90%, equivalent to 0.45 million cases would be the potential market for the product. The average units/patient for this cases is 3.2, thus the potential market in units is of 1.46 million units / year. Chronic anemia: the total current…

    • 661 Words
    • 3 Pages
    Good Essays
  • Powerful Essays

    Biopure Corp. Case Study

    • 1693 Words
    • 7 Pages

    Biopure Corporation Written Case Study I. Current Situation Audit A. Issue Oxyglobin and Hemopure are two blood substitutes that Biopure Corporation was developing. Oxyglobin was recently approved by the FDA for veterinary use while Hemapure is estimated to be approved in two years for human use. If Oxyglobin is launched it will be the first blood substitute for the veterinary market a small and price sensitive market. There is a perceived risk by Ted Jacobs, the VP of Human Clinical Trials…

    • 1693 Words
    • 7 Pages
    Powerful Essays
  • Satisfactory Essays

    Decision Sheet – Biopure Corporation Marketing Objective – Whether to launch Oxyglobin now or delay it till the approval of Hemopure. If yes, then devise a marketing plan for Oxyglobin. Options – 1. Launch Oxyglobin in the market immediately. 2. Defer the launch of Oxyglobin now till Hemopure release. Recommendation – Biopure Corporation should immediately launch Oxyglobin priced at $200. Rationale – Applying SWOT Analysis to the situation: Strengths 1. FDA approval has already come…

    • 599 Words
    • 3 Pages
    Satisfactory Essays
  • Good Essays

    Biopure Case

    • 1372 Words
    • 6 Pages

    Biopure Corporation: Case Write-Up Problem Definition In February 1998 Biopure Corporation faced a difficult decision regarding the launch of its newly developed “blood substitute” products. Biopure had developed “Hemopure”, a blood substitute for humans, and an ancillary product “Oxyglobin” for the veterinary market1. Hemopure was still in the process of gaining Federal Drug Administration (FDA) approval , while Oxyglobin had already been approved and was ready to be launched1. FDA approval was…

    • 1372 Words
    • 6 Pages
    Good Essays
  • Better Essays

    Biopure Case Study Report

    • 2663 Words
    • 11 Pages

    Biopure Case Study Executive Summary * Biopure Corporation developed two new products to enter into the field of blood substitutes: Hemopure, directed to the human market and Oxyglobin, for the veterinary market. Through the end of 1997 no blood substitute had received approval for use anywhere in the world. * What distinguishes both products from other “hemoglobin-based” blood substitutes is the fact that they are “bovine-sourced” as opposed to “human-sourced”, i.e. they are derived from…

    • 2663 Words
    • 11 Pages
    Better Essays